Literature DB >> 2942488

Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with teicoplanin.

C W Norden, K Niederreiter, E M Shinners.   

Abstract

Teicoplanin was used alone in the treatment of experimental osteomyelitis due to Staphylococcus aureus in rabbits. Treatment with 60 mg of teicoplanin/kg of body weight twice a day for 28 days failed to sterilize any infected rabbit bones. A possible explanation for the failure of teicoplanin may be that its in vitro activity against the infecting strain of S. aureus was substantially less under anaerobic conditions (at partial pressures of oxygen analogous to those in osteomyelitic rabbit bones) than under aerobic conditions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942488     DOI: 10.1007/bf01643479

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Experimental osteomyelitis. I. A description of the model.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1970-11       Impact factor: 5.226

2.  Teicoplanin.

Authors:  A H Williams; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1984-11       Impact factor: 5.790

3.  Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin.

Authors:  C W Norden; M Shaffer
Journal:  J Infect Dis       Date:  1983-02       Impact factor: 5.226

4.  Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

5.  Experimental osteomyelitis caused by Pseudomonas aeruginosa.

Authors:  C W Norden; E Keleti
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

6.  A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits.

Authors:  J T Mader; G L Brown; J C Guckian; C H Wells; J A Reinarz
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

  6 in total
  8 in total

1.  Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with LY146032.

Authors:  C W Norden; K Niederriter
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 2.  Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage.

Authors:  C Carbon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

3.  Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.

Authors:  Azzam Saleh-Mghir; Nourdine Ameur; Claudette Muller-Serieys; Farid Ismael; Françoise Lemaitre; Laurent Massias; Céline Feger; Rémy Bléton; Anne-Claude Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 4.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

5.  Efficacy of teicoplanin and autoradiographic diffusion pattern of [14C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses.

Authors:  A Saleh Mghir; A C Crémieux; R Bleton; F Ismael; M Manteau; S Dautrey; L Massias; L Garry; N Sales; B Mazière; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

6.  Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.

Authors:  Li-Yan Yin; Jason H Calhoun; Jacob K Thomas; Stuart Shapiro; Anne Schmitt-Hoffmann
Journal:  Antimicrob Agents Chemother       Date:  2008-03-10       Impact factor: 5.191

7.  Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus.

Authors:  H J Schaad; C Chuard; P Vaudaux; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

Review 8.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.